Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HAEMONETICS CORP Director's Dealing 2024

May 21, 2024

31565_dirs_2024-05-21_0832e866-7fa2-4952-99f8-f098575d0c52.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2024-05-17

Reporting Person: Strong Stewart W (President, Global Hospital)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-05-17 Common Stock F 284 $95.73 Disposed 15324 Direct
2024-05-17 Common Stock A 2872 Acquired 18196 Direct
2024-05-20 Common Stock M 2241 $56.57 Acquired 20437 Direct
2024-05-20 Common Stock F 1555 $95.08 Disposed 18882 Direct
2024-05-20 Common Stock S 686 $95.11 Disposed 18196 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-05-17 Non-qualified Stock Option (Right to Buy) $95.73 A 6313 Acquired 2031-05-17 Common Stock (6313) Direct
2024-05-20 Non-qualified Stock Option (Right to Buy) $56.57 M 2241 Disposed 2028-05-18 Common Stock (2241) Direct

Footnotes

F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2: This number includes unvested RSUs previously reported.

F3: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F4: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F5: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F6: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.

F7: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

F8: Reflects options granted on May 18, 2021 that vest in annual increments of 25% beginning on the first anniversary of the date of grant.